| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
BSB targets amyloid proteins, including extracellular amyloid-β (Aβ) plaques and intracellular lesions composed of abnormal tau and synuclein proteins. It is a Congo red-derived fluorescent probe that binds to these protein aggregates. It is a broad-spectrum amyloid imaging agent.
|
|---|---|
| ln Vitro |
In vitro, BSB is used as a fluorescent probe for amyloid imaging. It binds to extracellular amyloid beta protein and intracellular lesions composed of abnormal tau and synuclein proteins. It is used to study protein aggregation in neurodegenerative diseases.
|
| ln Vivo |
There are no significant in vivo applications for BSB as a therapeutic agent. It is a fluorescent probe for in vitro and ex vivo imaging of amyloid aggregates.
|
| Enzyme Assay |
The in vitro binding assay for BSB involves incubating the compound with tissue sections or protein aggregates and visualizing binding by fluorescence microscopy. The compound's binding to amyloid-β, tau, and synuclein aggregates is assessed.
|
| Cell Assay |
In vitro cell-based assays for BSB involve treating cells or tissue sections with the compound and visualizing binding to intracellular protein aggregates by fluorescence microscopy. The compound is used to study protein aggregation in cellular models of neurodegenerative diseases.
|
| Animal Protocol |
There are no standard in vivo animal experimental protocols for BSB as it is not administered to live animals for therapeutic purposes. It is a research tool for in vitro imaging.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of BSB are not characterized as it is not a drug. It is a fluorescent probe for research use.
|
| Toxicity/Toxicokinetics |
No toxicity data for BSB are available. As a research chemical, it should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
BSB is a Congo red-derived fluorescent probe for amyloid imaging. It binds to amyloid-β, tau, and synuclein aggregates. Its CAS number is 291766-06-8.
|
| Molecular Formula |
C24H17BRO6
|
|---|---|
| Molecular Weight |
481.292186498642
|
| Exact Mass |
480.021
|
| CAS # |
291766-06-8
|
| PubChem CID |
10184360
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
5.597
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
692
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1/C=C/C2=CC(=C(C=C2)O)C(=O)O)Br)/C=C/C3=CC(=C(C=C3)O)C(=O)O
|
| InChi Key |
ZVECSLHUCRIBDY-WMWQKROPSA-N
|
| InChi Code |
InChI=1S/C24H17BrO6/c25-20-13-16(2-1-14-5-9-21(26)18(11-14)23(28)29)4-8-17(20)7-3-15-6-10-22(27)19(12-15)24(30)31/h1-13,26-27H,(H,28,29)(H,30,31)/b2-1+,7-3+
|
| Chemical Name |
5-[(E)-2-[3-bromo-4-[(E)-2-(3-carboxy-4-hydroxyphenyl)ethenyl]phenyl]ethenyl]-2-hydroxybenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~207.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0777 mL | 10.3887 mL | 20.7775 mL | |
| 5 mM | 0.4155 mL | 2.0777 mL | 4.1555 mL | |
| 10 mM | 0.2078 mL | 1.0389 mL | 2.0777 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
